The study outlined in the news release from Eli Lilly and Company focuses on the efficacy and safety of imlunestrant, an investigational oral selective estrogen receptor degrader (SERD), in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC). This investigation into imlunestrant aims to provide valuable insights into breast cancer therapy options for this patient population. Here are the key points:
Key Question of the Study
The primary objective of the Phase 3 EMBER-3 study was to evaluate the effectiveness of imlunestrant as monotherapy and in conjunction with the CDK4/6 inhibitor abemaciclib (Verzenio) in patients with ER+, HER2- ABC whose disease had progressed on prior aromatase inhibitor therapy, with or without a CDK4/6 inhibitor.
Imlunestrant Breast Cancer Therapy Results
Monotherapy:
Imlunestrant significantly improved progression-free survival (PFS) compared to standard endocrine therapy (ET) in patients with ESR1 mutations. It reduced the risk of progression or death by 38% in this subgroup. The median PFS was 5.5 months with imlunestrant versus 3.8 months with standard ET.
Combination Therapy:
When used in combination with abemaciclib, imlunestrant reduced the risk of progression or death by 43% compared to imlunestrant alone in all patients, regardless of ESR1 mutation status.
Overall Population:
While imlunestrant alone did not significantly improve PFS compared to standard ET in the overall population, the combination of imlunestrant and abemaciclib showed a significant benefit across all patients.
Efficacy Implications for Future Clinical Practice
Targeted Therapy for ESR1 Mutations: Imlunestrant offers a promising option for patients with ER+, HER2- ABC who have developed ESR1 mutations, which are a common resistance mechanism to standard therapies. The significant improvement in PFS in this subgroup is particularly noteworthy.
All-Oral Regimen: The combination of imlunestrant and abemaciclib provides an all-oral treatment option, which is a significant advancement over current therapies that often require intramuscular injections (e.g., fulvestrant). This could enhance patient compliance and reduce side effects associated with injections, such as pain, swelling, or redness at the injection site.
Imlunestrant, both as monotherapy and in combination with abemaciclib, demonstrated a favorable safety profile with mostly low-grade and manageable adverse events. The discontinuation rate was relatively low at 6.3%, which is comparable to or better than existing combination regimens.
The ability of imlunestrant to penetrate the CNS and potentially target CNS metastases is an important feature, considering that CNS progression is a significant concern in advanced breast cancer. The post-hoc analysis indicated lower CNS progression rates with imlunestrant.
Future Directions
Imlunestrant is also being explored in the adjuvant setting for ER+, HER2- early breast cancer patients who have an increased risk of recurrence in the EMBER-4 trial, which could further expand its clinical utility.
In summary, the EMBER-3 study suggests that imlunestrant, particularly when used in combination with abemaciclib, could become a valuable treatment option for patients with ER+, HER2- advanced breast cancer. It offers improved efficacy, notably in those with ESR1 mutations, as well as a more convenient and tolerable all-oral regimen.
